Cargando…

Psychedelic microdosing benefits and challenges: an empirical codebook

BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Thomas, Petranker, Rotem, Christopher, Adam, Rosenbaum, Daniel, Weissman, Cory, Dinh-Williams, Le-Anh, Hui, Katrina, Hapke, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883/
https://www.ncbi.nlm.nih.gov/pubmed/31288862
http://dx.doi.org/10.1186/s12954-019-0308-4
_version_ 1783433793592360960
author Anderson, Thomas
Petranker, Rotem
Christopher, Adam
Rosenbaum, Daniel
Weissman, Cory
Dinh-Williams, Le-Anh
Hui, Katrina
Hapke, Emma
author_facet Anderson, Thomas
Petranker, Rotem
Christopher, Adam
Rosenbaum, Daniel
Weissman, Cory
Dinh-Williams, Le-Anh
Hui, Katrina
Hapke, Emma
author_sort Anderson, Thomas
collection PubMed
description BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. METHODS: In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. RESULTS: We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. CONCLUSIONS: These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12954-019-0308-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6617883
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66178832019-07-22 Psychedelic microdosing benefits and challenges: an empirical codebook Anderson, Thomas Petranker, Rotem Christopher, Adam Rosenbaum, Daniel Weissman, Cory Dinh-Williams, Le-Anh Hui, Katrina Hapke, Emma Harm Reduct J Research BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. METHODS: In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. RESULTS: We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. CONCLUSIONS: These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12954-019-0308-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-10 /pmc/articles/PMC6617883/ /pubmed/31288862 http://dx.doi.org/10.1186/s12954-019-0308-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Anderson, Thomas
Petranker, Rotem
Christopher, Adam
Rosenbaum, Daniel
Weissman, Cory
Dinh-Williams, Le-Anh
Hui, Katrina
Hapke, Emma
Psychedelic microdosing benefits and challenges: an empirical codebook
title Psychedelic microdosing benefits and challenges: an empirical codebook
title_full Psychedelic microdosing benefits and challenges: an empirical codebook
title_fullStr Psychedelic microdosing benefits and challenges: an empirical codebook
title_full_unstemmed Psychedelic microdosing benefits and challenges: an empirical codebook
title_short Psychedelic microdosing benefits and challenges: an empirical codebook
title_sort psychedelic microdosing benefits and challenges: an empirical codebook
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883/
https://www.ncbi.nlm.nih.gov/pubmed/31288862
http://dx.doi.org/10.1186/s12954-019-0308-4
work_keys_str_mv AT andersonthomas psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT petrankerrotem psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT christopheradam psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT rosenbaumdaniel psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT weissmancory psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT dinhwilliamsleanh psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT huikatrina psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook
AT hapkeemma psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook